Oxybutynin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Use in Detrusor Instability

Drugs & Aging

Volumn 6, Issue 3, 1995, Pages 243-262

  Yarker, Yvonne E ^a   Goa, Karen L ^a   Fitton, Andrew ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MANDELIC ACID DERIVATIVE; OXYBUTYNIN;

ANIMAL; BLADDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; INNERVATION; MALE; METABOLISM; PATHOPHYSIOLOGY; REVIEW; URINE INCONTINENCE;

ANIMAL; BLADDER; COMPARATIVE STUDY; DRUG EVALUATION; FEMALE; HUMAN; MALE; MANDELIC ACIDS; PARASYMPATHOLYTICS; URINARY INCONTINENCE;

EID: 0029265229     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199506030-00007     Document Type: Article

References (80)

1. Drugs in focus: 11. Oxybutynin hydrochloride
2. Autonomic innervation of the urinary bladder and urethra. Chapter 9: Nervous Control of the Urogenital System
3. Standardisation of terminology of lower urinary tract function
4. The management of detrusor instability
5. Management of detrusor instability
6. The unstable bladder
7. Current concepts in the treatment of disorders of micturition
8. Etiology and management of detrusor instability and mixed incontinence
9. Response to treatment of detrusor instability in relation to psychoneurotic status
10. The unstable bladder: towards a common mechanism
11. Urinary incontinence in the community — analysis of a MORI poll
12. Incontinence in institutions: costs and contributing factors
13. Urinary incontinence in the community. Common and can often be successfully treated
14. The costs of urinary incontinence
15. Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder
16. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors
17. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine
18. Mini-pig urinary bladder function: comparisons of in vitro anticholinergic responses and in vivo cystometry with drugs indicated for urinary incontinence
19. In vitro intravesical instillation of anticholinergic, antispasmodic and calcium blocking agents (rabbit whole bladder model)
20. Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle
21. Analysis of the in vitro pharmacologie response of renal pelvis and detrusor smooth muscle to thiphenamil, oxybutynin and verapamil
22. Current concepts in the treatment of genitourinary tract disorders in the older individual
23. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay
24. 3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs
25. Evaluation of mRNA encoding muscarinic receptor subtypes in human detrusor muscle [abstract]
26. Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites
27. Identification and characterization of muscarinic cholinergic receptors in the human urinary bladder and parotid gland
28. A study on the affinities of various muscarinic antagonists to the human detrusor muscle [in Japanese]
29. Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride)
30. Comparison of calcium antagonist properties of antispasmotic agents
31. Effects of intravesically administered anticholinergics, β-adrenergic stimulant and α-adrenergic blocker on bladder function in unanesthetized rats
32. Effects of selective cholinergic antagonists and α,β-methylene ATP on guinea-pig urinary bladder contractions in vivo following pelvic nerve stimulation
33. Effect of oxybutynin on reflex micturition in the decerebrate dog as determined by urodynamic evaluation
34. Relaxation of intestinal bladders by intravesical oxybutynin chloride
35. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers
36. The pharmacokinetics of oxybutynin in man
37. Intravesical administration of oxybutynin: mode of action in controlling detrusorhyperreflexia [abstract 64]
38. Effect of food on the pharmacokinetics of oxybutynin in normal subjects [abstract]
39. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients
40. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment
41. Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial [in Japanese]
42. Clinical effects of 1mg tablets of oxybutynin hydrochloride on patients with unstable bladders and neurogenic bladders [in Japanese]
43. Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder [in Japanese]
44. R tablets) in the elderly [in Japanese]
45. R). Especíally for the treatment of pollakisuria, urgency and urinary incontinence [in Japanese]
46. The use of oxybutynin in urological practice
47. Oxybutynin hydrochloride in the management of detrusor instability
48. Response of geriatric urinary incontinence to treatment with oxybutynin chloride
49. Oxybutonin with bladder retraining for detrusor instability in the elderly — a placebo controlled trial [abstract]
50. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability
51. Does oxybutynin enhance the effectiveness of prompted voiding for incontinence among nursing home residents? [abstract no. A3]
52. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study [see comments]
53. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebocontrolled study [see comments]
54. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia
55. Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial
56. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo
57. Treatment of bladder instability and urge incontinence with propiverin hydrochloride (Mictonorm) and oxybutinin chloride — a randomized cross-over trial [in German]
58. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride
59. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia
60. Topical oxybutynin chloride for relaxation of dysfunctional bladders
61. Intravesical oxybutynin chloride: experience with 42 patients
62. Intravesical administration of oxybutynin in spinal cord injury patients [abstract]
63. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia
64. Effects of local intravesical oxybutynin therapy in women with dysfunctional bladder [abstract]
65. Low dose oxybutynin for the unstable bladder [letter]
66. R) [in French]
67. Oxybutynin: is it safe?
68. Oxybutynin-induced reflux esophagitis
69. Pseudo-obstruction secondary to anticholinergic drugs in Parkinson’s disease [letter]
70. Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial
71. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence [abstract]
72. Effects of the anticholinergic drug prifinium bromide on urinary bladder contractions in rat in vivo and in guinea-pig in vitro
73. Poisoning with oxybutynin
74. Bladder autoaugmentation: early clinical experience